Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL
Sponsor: Georgetown University
Terminated
Recruitment difficulties and toxicity
Other terminated trials from Georgetown University
Other Chronic Lymphocytic Leukemia trials with similar outcome
This PHASE1 trial investigates Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and is currently terminated or withdrawn. Georgetown University leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Jun 2017 — Feb 2018 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Apr 2017 — Jun 2017 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Georgetown University
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .